Zhao Meimei, Cao Yongtong, Ma Liang
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
BMC Nephrol. 2025 Feb 11;26(1):72. doi: 10.1186/s12882-025-03953-3.
Diabetic kidney disease (DKD) represents the predominant and severe microvascular complication associated with diabetes, frequently culminating in End-Stage Kidney Disease (ESKD). The escalating prevalence of diabetes has correspondingly led to a rise in DKD incidence, imposing significant challenges on both individuals and society. The etiology of DKD is multifaceted and remains devoid of definitive therapeutic interventions. This article examines the pharmacological actions and mechanisms of different drugs used for the prevention and treatment of DKD that are currently in clinical use or undergoing development. The goal is to offer insights for early intervention based on therapeutic combinations to potentially slow kidney disease progression.
糖尿病肾病（DKD）是与糖尿病相关的主要且严重的微血管并发症，常发展至终末期肾病（ESKD）。糖尿病患病率的不断上升相应地导致了DKD发病率的增加，给个人和社会都带来了重大挑战。DKD的病因是多方面的，且仍然缺乏明确的治疗干预措施。本文探讨了目前正在临床使用或研发中的用于预防和治疗DKD的不同药物的药理作用和机制。目的是基于治疗组合为早期干预提供见解，以潜在地减缓肾病进展。
